Why the study?
Does prophylactic N-acetylcysteine improve postoperative lung function or reduce atelectasis in lung healthy patients undergoing elective upper laparotomy?
Does prophylactic N-acetylcysteine improve postoperative lung function or reduce atelectasis in lung healthy patients undergoing elective upper laparotomy?
Prophylactic systemic administration of N-acetylcysteine does not improve postoperative lung function or reduce atelectasis in lung healthy patients undergoing elective upper laparotomy.
Prophylactic NAC should not be used for lung protection after upper laparotomy; confirms no benefit versus placebo in this RCT population.
In a randomized, double-blind study, 131 consecutive patients, subjected to elective upper laparotomy, were prophylactically given the recommended dose of N-acetylcysteine (NAC) (Mucomyst, ASTRA) (200 mg x 3) or placebo against postoperative pulmonary complications. The effect was evaluated by lung function tests (VC and FEV1), arterial blood gas analyses and chest x-ray. No benefit could be demonstrated, either to postoperative pulmonary function or in the frequency of atelectasis in the recommended dose. However, no patients with preoperative bronchopulmonary disease demanding treatment with bronchodilatators were included in the study. A positive effect of NAC in this category of patients could not be excluded.
No takes yet. Share an insight, caveat, or question.
Jepsen et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: